Date: 2015-04-15
Type of information: Series B financing round
Company: Myokardia (USA - CA)
Investors: Casdin Capital (USA - NY) Cormorant Asset Management (USA - MA) Perceptive Life Sciences (USA - NY) BridgeBio (USA - CA) Sanofi (France)
Amount: $46 million
Funding type: series B financing round
Planned used: Proceeds from the financing will be used to advance and expand Myokardia’s portfolio of potential therapies for hypertrophic and dilated cardiomyopathies, including its lead drug candidate, MYK-461, which is currently in Phase 1 clinical trials. MYK-461 targets one of the most common molecular mechanisms causing hypertrophic cardiomyopathy, and aims to correct the overcontraction driving the disease process and restore cardiac contractility to normal levels. MyoKardia believes this approach has the potential to stop and potentially reverse disease progression. MYK-461’s clinical program will evaluate HCM patients whose disease is caused by this specific mechanism, as identified by genetic screening.
Others: * On April 30, 2015, MyoKardia announced the successful completion of a $46 million Series B financing. This financing included investments from an undisclosed public investment fund, Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences, an affiliate of Cowen Group, and BridgeBio LLC. Existing investor Sanofi also participated in the financing.
Therapeutic area: Cardiovascular diseases
